Dayanna Hartmann Cambruzzi Mendes

Dayanna Hartmann Cambruzzi Mendes

Auto-generated profile, based on publicly available information

Dayanna Hartmann Cambruzzi Mendes

Instituto Federal do Parana

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
EGElizama de Gregório
Elizama de Gregório
LPLuan Henrique Patrzyk
Luan Henrique Patrzyk
AFAnne Karine Bosetto Fiebrantz
Anne Karine Bosetto Fiebrantz
Juliana Sartori BoniniJuliana Sartori Bonini
Juliana Sartori Bonini
DCDayanna Hartmann Cambruzzi
Dayanna Hartmann Cambruzzi
WSWeber Cláudio Francisco Nunes da Silva
Weber Cláudio Francisco Nunes da Silva
SUMMARY OBJECTIVE: We studied the users of the Specialized Drug Distribution Program of the public health network. METHODS: A prospective cohort examined the elderly at two intervals of three years and included 30 patients in phase I and 16 in phase II. The methodology was composed of home visits, anthropometric, nutritional and hematological evaluation. For the progression of AD, the Clinical Dementia Rating (CDR) scale was used. RESULTS: According to the CDR, the disease evolved, since in 2014 most of the patients were in CDR 3. In the analysis of the micronutrients, only the B vitamins (B1, B2, B3, B5, B6) presented a significant reduction in 2014. The consumption of carbohydrates and lipids increased in the 2014 evaluation, and protein consumption decreased. As for the average weight of the elderly, there was an increase in 2014, 65.9 (± 15.6) Kg, with a BMI of 26.75 (± 4, 5), in 2011 the average weight was 62.44 kg (± 14, 36), BMI 24.64 (± 4.97). CONCLUSION: The hypothesis that patients are likely to be overweight or obese before the development of AD and that this may be associated with an increased risk of dementia is suggested.

29 November 2017 in F1000Research
Verified
Journal Article
Open access
PDF file
FVFelipe Nathanael Coelho Vaz
Felipe Nathanael Coelho Vaz
LTLuana Bortoluzzi Trombim
Luana Bortoluzzi Trombim
GFGuilherme Barroso L. de Freitas
Guilherme Barroso L. de Freitas
MHMaria Vaitsa Loch Haskel
Maria Vaitsa Loch Haskel
GSGiovana dos Santos
Giovana dos Santos
Juliana Sartori BoniniJuliana Sartori Bonini
Juliana Sartori Bonini
Background: Elderly patients frequently have concomitant diseases, triggering the necessity of utilizing several different medications, which can cause adverse events associated with therapy, called polypharmacy. This study aimed to evaluate the main concomitant diseases with Alzheimer's disease (AD) and discuss possible interactions between drugs utilized to treat dementia and its comorbidities, and indicate safe medicines for patients with AD. Methods: 41 individuals with AD who withdraw medicines for dementia from the Brazilian public health system (SUS) participated in this study. Data collection was performed using three questionnaires: 1) Clinical Dementia Rating, to verify disease stage; 2) Mini–mental state examination, to measure cognitive impairment; and 3) Sociodemographic analysis, to evaluate concomitant diseases, utilized drugs, drug-drug interactions, among other demographic variables. Statistical analyses were performed using SPSS and data was presented as relative frequency. Results: The results of this study showed that the most frequent concomitant diseases with AD are: systemic arterial hypertension, depression, diabetes mellitus, and hypercholesterolemia. Polypharmacy was observed in 95.12% of patients. The pharmacologic classes that presented interactions with AD medications were anxiolytics, antidepressants, antipsychotics, antihypertensives, and antidiabetics. Conclusion: In the present study, polypharmacy in patients with AD and other concomitant diseases has been characterized. The average number of drugs that these patients ingested was seven per day, and this leads to drug interactions, which are potentially damaging to the body. Consequently, we have tried to reduce these interactions, by suggesting drugs that are safer, for example furosemide instead of amlodipine to treat hypertension.

1 February 2018 in F1000Research
Verified
Journal Article
Open access
PDF file
EGElizama de Gregorio
Elizama de Gregorio
DMDayanna Hartmann Cambruzzi Mendes
Dayanna Hartmann Cambruzzi Mendes
LPLuan Henrique Patrzyk
Luan Henrique Patrzyk
LFLuana Felski
Luana Felski
GFGuilherme Barroso Langoni de Freita
Guilherme Barroso Langoni de Freita
WSWeber Cláudio Francisco Nunes da Silva
Weber Cláudio Francisco Nunes da Silva
Introduction: Dementia is a common health problem in elderly people, Alzheimer disease (AD) being the most prevalent. AD can be considered as a cause of death and must be registered on the death certificate of the patients. However, most of the time, the main cause of death registered is not related to AD, but as an underlying or contributing cause. For example, individuals who have AD and die from myocardium infarction. This study aimed to analyze if nutritional status was associated with survival and mortality for AD, and if AD was reported as actual cause of death on the death certificate Methods: The study was carried out as a cross-sectional study with elderly citizens of the community registered in the National Health System (SUS), with cognitive, nutritional, biochemical and hematological evaluations of 30 AD patients in Guarapuava, Paraná state, Brazil. Results: Significant differences were not observed between live and dead patients when evaluated considering the methods applied. Only 22% of the death certificates stated death due to AD. The patient’s cause of death showed a strong relation to respiratory issues; potential explanations based on immunological, biochemical and comorbidity were not confirmed on this study. Conclusions: AD was not declared as the cause of death in the majority of certificates, contributing to the underreporting and reducing the information of death due to AD in the country.

26 May 2023 in Peer Review
Verified
Journal Article
Closed access
PDF file
GHGlaucia Hilgemberg
Glaucia Hilgemberg
SPSuzana Botão Ayres Pereira
Suzana Botão Ayres Pereira
DZDébora Giaretta Zatta
Débora Giaretta Zatta
DCDayanna Hartmann Cambruzzi
Dayanna Hartmann Cambruzzi
ECEmerson Carraro
Emerson Carraro
Todos os casos de intoxicação exógena são eventos de notificação compulsória, com preenchimento semanal do Sistema de Informação de Agravos de Notificação (Sinan), no entanto, uma estimativa de que apenas 20% dos casos são de fato notificados. Por meio de uma análise documental retrospectiva, descritiva, quantitativa, longitudinal entre 2015 e 2020, foi realizada a tabulação dos dados do Sinan, Siagro, ADAPAR e IBGE, e foram determinadas variáveis relevantes para a melhor compreensão do cenário paranaense atual quanto à comercialização e ao uso de agroquímicos, bem como às intoxicações exógenas. Obteve-se um cenário amplamente distorcido no que se refere à incidência geográfica dos agravos de saúde caracterizados como intoxicações exógenas, além disso, foi identificado um importante pico de notificações após a implantação da portaria que torna compulsória a notificação desse tipo de evento, ainda que haja uma importante incidência média de eventos cujas causas foram listadas como ignorado ou em branco (6,96%), além de volumes alarmantes de agroquímicos comercializados dentre as classes menos potencialmente.

24 June 2020 in F1000Research
Verified
Journal Article
Open access
PDF file
DMDayanna Hartmann Cambruzzi Mendes
Dayanna Hartmann Cambruzzi Mendes
GHGlaucia Renee Hilgemberg
Glaucia Renee Hilgemberg
FPFlavio Silva Posseti
Flavio Silva Posseti
JWJéssica Wouk
Jéssica Wouk
ECEmerson Carraro
Emerson Carraro
Introduction: Alzheimer's disease (AD) is a public health problem in Brazil due to the growing number of older adults in this population. Knowing the prevalence of AD in the Paraná state is essential to improve patients’ quality of life. The objective of the study was to estimate AD prevalence in the state of Paraná, based on the prescription of anticholinesterases, from 2012 to 2017. Methods: Patients diagnosed with AD, aged 60 years or over, who used Brazil’s Unified Public Health System (SUS) and received AD medication from the Department of Pharmaceutical Assistance of the state of Paraná, from 2012 to 2017, were the target population of the present study. The medication data were collected from the Computerized system management and Monitoring of Exceptional Drugs (SISMEDEX), and the population’s data were collected from the Brazilian Institute of Geography and Statistics (IBGE). Results: The sample consisted of 52,687 patients, and the median prevalence of AD in the established period for the state was 642.6/100,000 inhabitants (0.64%). In all ages and macro-regions, women showed the highest prevalence rates. The median prevalence for women in the established period was 755.4/100,000 inhabitants (0.75%). Among men, the median prevalence was 510.2/100,000 inhabitants (0.51%). In the temporal analysis of prevalence, between 2012 and 2017, a reduction of 23% was found in the state rate. The prevalence rate of Paraná for AD is nine times lower than the Brazilian average. Conclusions: Paraná’s prevalence rate for AD is lower than the rates of Brazil and the world, suggesting that AD is underdiagnosed in most municipalities of this state.